首页> 外文期刊>Protein Science: A Publication of the Protein Society >In silico and in vitro studies to elucidate the role of Cu(2+) and galanthamine as the limiting step in the amyloid beta (1-42) fibrillation process.
【24h】

In silico and in vitro studies to elucidate the role of Cu(2+) and galanthamine as the limiting step in the amyloid beta (1-42) fibrillation process.

机译:在硅和体外研究中,以阐明Cu(2+)和Galanthamine作为淀粉样蛋白β(1-42)原纤化过程中的限制步骤的作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The formation of fibrils and oligomers of amyloid beta (Aβ) with 42 amino acid residues (Aβ1-42 ) is the most important pathophysiological event associated with Alzheimer's disease (AD). The formation of Aβ fibrils and oligomers requires a conformational change from an α-helix to a β-sheet conformation, which is encouraged by the formation of a salt bridge between Asp 23 or Glu 22 and Lys 28. Recently, Cu(2+) and various drugs used for AD treatment, such as galanthamine (Reminyl(?) ), have been reported to inhibit the formation of Aβ fibrils. However, the mechanism of this inhibition remains unclear. Therefore, the aim of this work was to explore how Cu(2+) and galanthamine prevent the formation of Aβ1-42 fibrils using molecular dynamics (MD) simulations (20 ns) and in vitro studies using fluorescence and circular dichroism (CD) spectroscopies. The MD simulations revealed that Aβ1-42 acquires a characteristic U-shape before the α-helix to β-sheet conformational change. The formation of a salt bridge between Asp 23 and Lys 28 was also observed beginning at 5 ns. However, the MD simulations of Aβ1-42 in the presence of Cu(2+) or galanthamine demonstrated that both ligands prevent the formation of the salt bridge by either binding to Glu 22 and Asp 23 (Cu(2+) ) or to Lys 28 (galanthamine), which prevents Aβ1-42 from adopting the U-characteristic conformation that allows the amino acids to transition to a β-sheet conformation. The docking results revealed that the conformation obtained by the MD simulation of a monomer from the 1Z0Q structure can form similar interactions to those obtained from the 2BGE structure in the oligomers. The in vitro studies demonstrated that Aβ remains in an unfolded conformation when Cu(2+) and galanthamine are used. Then, ligands that bind Asp 23 or Glu 22 and Lys 28 could therefore be used to prevent β turn formation and, consequently, the formation of Aβ fibrils.
机译:用42个氨基酸残基(Aβ1-42)的淀粉样蛋白β(Aβ)的原纤维和低聚物形成与阿尔茨海默病(AD)相关的最重要的病理生理事件。 Aβ原纤维和低聚物的形成需要从α-螺旋到β-片状构象的构象变化,这通过在ASP 23或Glu 22和Lys 28之间形成盐桥来鼓励。最近,Cu(2+)据报道,已经据报道,用于AD处理的各种药物,例如Galanthamine(Reminyl(α))以抑制Aβ原纤维的形成。然而,这种抑制的机制仍然不清楚。因此,这项工作的目的是探讨Cu(2+)和Galanthamine如何使用分子动力学(MD)模拟(20ns)和使用荧光和圆形二色性(CD)光谱的体外研究形成β1-42原纤维的形成。 MD模拟显示Aβ1-42在α-Helix之前获取特征U形,以β-薄板构象变化。在5 ns开始,也观察到ASP 23和Lys 28之间的盐桥的形成。然而,在Cu(2+)或Gal anthamine存在下Aβ1-42的MD模拟证明了两个配体通过与Glu 22和Asp 23(Cu(2+))或液体结合来防止盐桥的形成28(Galthamine),其防止Aβ1-42采用允许氨基酸转变为β-片状构象的U-特征构象。对接结果表明,通过从1Z0Q结构的单体的MD模拟获得的构象可以形成与从低聚物中的2BGE结构获得的相互作用。体外研究表明,当使用Cu(2+)和加花胺时,Aβ保持展开的构象。然后,因此可以使用结合ASP 23或Glu 22和Lys 28的配体来防止β转化形成,并且因此,形成Aβ原纤维。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号